Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-5110PMID 19010854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Validating a prognostic model

  2006cited by this paper
• Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma

  2006cited by this paper
• Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.

  2006cited by this paper
• Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.

  2005cited by this paper
• Serum Levels of Hepatocyte Growth Factor in Patients with Breast Cancer

  2005cited by this paper
• Concordance probability and discriminatory power in proportional hazards regression

  2005cited by this paper
• Hepatocyte growth factor/scatter factor and prostate cancer: a review.

  2005cited by this paper
• Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer.

  2005cited by this paper
• Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy.

  2004cited by this paper
• Targeting the HGF/SF receptor c‐met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells

  2004cited by this paper
• Evaluating a New Marker’s Predictive Contribution

  2004cited by this paper
• A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.

  2003cited by this paper
• Expression of c-met Tyrosine Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas

  2003cited by this paper
• The HGF/SF antagonist NK4 reverses fibroblast‐ and HGF‐induced prostate tumor growth and angiogenesis in vivo

  2003cited by this paper
• Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase–polymerase chain reaction

  2003cited by this paper
• Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

  2003cited by this paper
• Lymph Node Staging in Clinically Localized Prostate Cancer

  2003cited by this paper
• High expression of the Met receptor in prostate cancer metastasis to bone.

  2002cited by this paper
• Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.

  2002cited by this paper
• Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.

  2001cited by this paper
• The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant.

  2001cited by this paper
• Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.

  2001cited by this paper
• Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells.

  2000cited by this paper
• Significant Correlation between Serum Level of Hepatocyte Growth Factor and Progression of Gastric Carcinoma

  1999cited by this paper
• Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers.

  1999cited by this paper
• Lymph node staging in clinically localized prostate cancer

  1999cited by this paper
• Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

  1997cited by this paper
• Involvement of hepatocyte growth factor in increased integrin expression on HepG2 cells triggered by adhesion to endothelial cells.

  1997cited by this paper
• A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates.

  1997cited by this paper
• Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma

  1997cited by this paper
• Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.

  1997cited by this paper
• Longitudinal screening for prostate cancer with prostate-specific antigen.

  1996cited by this paper
• Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

  1995cited by this paper
• c-met proto-oncogene expression in benign and malignant human prostate tissues.

  1995cited by this paper
• Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. A publication of the cancer committee, college of american pathologists. Task Force on the Examination of Specimens Removed From Patients With Prostate Cancer.

  1994cited by this paper
• Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer.

  1994cited by this paper
• Cancer statistics

  1989cited by this paper

• An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies

  2022cites this paper
• Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer

  2021cites this paper
• HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence

  2021cites this paper
• Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.

  2020cites this paper
• Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis.

  2019cites this paper
• Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors.

  2019cites this paper
• Targeting HGF with Antibodies as an Anti‐Cancer Therapeutic Strategy

  2018cites this paper
• Implication du récepteur à activité tyrosine kinase (RTK) MET sur la balance survie/apoptose et identification de nouvelles mutations de RTKs dans les cancers colorectaux métastatiques

  2018cites this paper
• Importance de la co-dérégulation des voies RAS/MAPK et PI3K/AKT/mTOR dans la transformation épithéliale prostatique. Approche in vivo à l'aide d'un modèle dans les glandes accessoires de la Drosophile

  2018cites this paper
• Increased ARF6 activation correlates with HGF stimulation in non-invasive prostate cancer cells

  2018influential citation
• Increased ARF 6 activation correlates with HGF stimulation in non-invasive prostate cancer cells

  2018influential citation
• Hepatocyte growth factor/MET in cancer progression and biomarker discovery

  2017cites this paper
• Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR

  2017cites this paper
• Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

  2017cites this paper
• Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer

  2017cites this paper
• Distinct Osteomimetic Response of Androgen‐Dependent and Independent Human Prostate Cancer Cells to Mechanical Action of Fluid Flow: Prometastatic Implications

  2017cites this paper
• Pelvic Lymph Node Dissection in Prostate Cancer: Indications, Extent and Tailored Approaches

  2017cites this paper
• Mechanistic Support for Combined MET and AR Blockade in Castration

  2016cites this paper
• In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B

  2016cites this paper
• Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial

  2016cites this paper
• Identiication of Biomarkers for Prostate Cancer

  2016cites this paper
• Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer

  2016cites this paper
• SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma

  2016cites this paper
• Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer

  2016cites this paper
• Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

  2016cites this paper
• Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

  2015cites this paper
• Targeting C-Met/VEGF in Castration Resistant Prostate Cancer

  2014cites this paper
• The role of the WASP family proteins in cellular migration and invasion in prostate cancer

  2014cites this paper
• Identification of Biomarkers for Prostate Cancer

  2014cites this paper
• Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.

  2014cites this paper
• Tight Junctions in Cancer Metastasis

  2013cites this paper
• Enhanced Vascular Permeability in Solid Tumors: A Promise for Anticancer Nanomedicine

  2013cites this paper
• Targeting bone physiology for the treatment of metastatic prostate cancer.

  2013cites this paper
• Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells

  2013cites this paper
• Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions

  2013cites this paper
• Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.

  2013cites this paper
• HGF (hepatocyte growth factor (hepapoietin A; scatter factor))

  2012cites this paper
• Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607

  2012cites this paper
• Signaling Pathways and Molecular Mediators in Metastasis

  2012cites this paper
• Clinical development of novel therapeutics for castration‐resistant prostate cancer

  2012cites this paper
• Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor.

  2012cites this paper
• Hepatocyte Growth Factor is a Potential Lymphangiogenic Factor; Clinical Implications

  2011cites this paper
• The PCa Tumor Microenvironment

  2011cites this paper
• The Aromatase Gene (CYP19A1) Variants and Circulating Hepatocyte Growth Factor in Postmenopausal Women

  2011cites this paper
• Detection of Hepatocyte Growth Factor (HGF) Ligand-c-MET Receptor Activation in Formalin-Fixed Paraffin Embedded Specimens by a Novel Proximity Assay

  2011cites this paper
• Impact of Tumor Hypoxia, Src, and Met Signaling in the Dissemination of Tumor Cells

  2011cites this paper
• A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

  2011cites this paper
• Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic–pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inh

  2011cites this paper
• The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

  2011cites this paper
• Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.

  2010cites this paper
• Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model.

  2010cites this paper
• Recombinant kringle 5 from plasminogen antagonises hepatocyte growth factor-mediated signalling.

  2010cites this paper
• BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor–Stimulated Prostate Cancer Metastatic Phenotype In vitro

  2010cites this paper
• Analysis of novel targets in the pathobiology of prostate cancer

  2009cites this paper
• DEVELOPMENT OF NOVEL ASSAYS FOR MEASURING DIFFERENT MOLECULAR FORMS OF PROSTATE SPECIFIC ANTIGEN

  2009cites this paper
• Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors.

  2009cites this paper
• Development of Novel Assays for Measuring Different Molecular Forms of Prostate Specific Antigen

  2009cites this paper